Rabies Diagnostics Market Report 2026

Rabies Diagnostics Market Overview

• Rabies Diagnostics market size has reached to $1.78 billion in 2025 • Expected to grow to $2.45 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Increasing Prevalence Of Rabies Propel The Growth Of The Market For Rabies • Market Trend: Innovative Rabies Antibody Test Kits Drive Market Leadership In Rabies Diagnostics • North America was the largest region in 2025.

What Is Covered Under Rabies Diagnostics Market?

Rabies diagnostics refers to the process of identifying Rabies disease based on the condition and symptoms. It is a preventable viral illness that is most commonly spread via a rabid animal's bite. Rabies can be diagnosed once the rabies virus is found in any portion of the infected animal's brain. In humans, saliva, serum, spinal fluid, and skin biopsies of hair follicles at the nape of the neck are tested for diagnosis. The methods involved in rabies diagnostics are fluorescent antibody tests, immunohistochemical tests, amplification methods, histologic examinations, and serology tests. The fluorescent antibody test (FA) refers to a diagnostic test based on the finding that rabies virus proteins (antigen) are present in the tissues of animals infected with the virus. The technologies include ELISA/immunohistochemistry, chromatography techniques, PCR, and others used by hospitals, diagnostic centers, cancer palliative care clinics, and other end-users such as pharmacies.

What Is The Rabies Diagnostics Market Growth Forecast?

The rabies diagnostics market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to adoption of ai-powered diagnostic tools, rising demand for rapid point-of-care tests, expansion of mobile-based disease surveillance, innovation in molecular and serology techniques, increasing public-private collaborations for rabies eradication. Major trends in the forecast period include rapid point-of-care rabies testing, advanced molecular diagnostic techniques, integration of ai in rabies detection, mobile-based rabies surveillance solutions, high-sensitivity serology testing.

Global Rabies Diagnostics Market Segmentation

1) By Diagnostic Method: Fluorescent Antibody Test, Immunohistochemical Test, Amplification Methods, Histologic Examination, Serology Tests 2) By Technology: ELISA Or Immunohistochemistry, Chromatography Techniques, PCR, Other Technologies 3) By End-User: Hospital, Diagnostic Centers, Cancer Palliative Care Clinics, Other End-Users Subsegments: 1) By Fluorescent Antibody Test: Direct Fluorescent Antibody Test (DFA) 2) By Immunohistochemical: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting 3) By Amplification Methods: Polymerase Chain Reaction (PCR), Reverse Transcription PCR (RT-PCR) 4) By Histologic Examination: Microscopic Examination, Tissue Staining Techniques 5) By Serology Tests: Virus Neutralization Test (VNT), Enzyme-Linked Immunosorbent Assay (ELISA)

What Is The Driver Of The Rabies Diagnostics Market?

The increasing prevalence of rabies is expected to propel the growth of the market for rabies diagnostics. Rabies is a preventable viral illness that is most commonly spread via a rabid animal's bite. The rabies virus attacks mammals' central nervous systems, eventually causing brain damage and leading to death. Rabies diagnosis is used to detect the rabies virus in humans and animals using a variety of diagnostic tests and techniques. Additionally, the rising cases of infectious animal-transmitted diseases have favored the demand for rabies diagnostics. For instance, in April 2024, according to the South Dakota Department of Health (SD DOH), a US-based government administration, in 2023, South Dakota reported 20 animals testing positive for rabies (Table 1), representing a 122% increase compared with 2022, when 9 cases were identified. Of the rabid animals, one was a domestic animal (a cow) and the remaining 19 were wild animals, including 18 bats and 1 skunk. Therefore, the increasing prevalence of rabies will drive the rabies diagnostics industry.

Key Players In The Global Rabies Diagnostics Market

Major companies operating in the rabies diagnostics market are Bio-Rad Laboratories Inc., The Merck Group, Aviva Systems Biology Corporation, Creative Diagnostics, Demeditec Diagnostics GmbH, Abbexa Ltd., Norgen Biotek Corp., BioNote Inc., Express Biotech International Inc., MyBioSource Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., Fluidigm Corp., Bio-X Diagnostics S.A., Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Heska Corporation, IDEXX Laboratories Inc., InBios International Inc., KHB Shanghai Kehua Bio-Engineering Co. Ltd., Meridian Bioscience Inc., MP Biomedicals LLC, Neogen Corporation, Randox Laboratories Ltd., SDIX LLC, Sigma-Aldrich Corporation

Global Rabies Diagnostics Market Trends and Insights

Major companies operating in the rabies diagnostic market are developing innovative products, such as rabies antibody test kits, to sustain their position in the market. A rabies antibody test kit is a diagnostic tool used to detect antibodies in the blood to assess immunity or the need for additional rabies vaccination. For instance, in February 2024, BioStone Animal Health, a US-based diagnostic company, launched AsurDx. The rabies antibody test kit detects antibodies specific to the rabies virus in mammalian serum samples using a rapid and sensitive ELISA method. It provides a cost-effective solution for assessing rabies immunity, suitable for both vaccinated animals and those at risk. The kit is designed for simple use and delivers reliable results. It helps ensure animals meet the standard of 0.5 international units (UL) per ml for immune activity against rabies.

What Are Latest Mergers And Acquisitions In The Rabies Diagnostics Market?

In November 2025, Zoetis Inc., a US based provider of animal health medicines, vaccines, and comprehensive veterinary diagnostic services, acquired Veterinary Pathology Group (VPG) for an undisclosed amount. With this acquisition, Zoetis expanded its veterinary diagnostics footprint in the United Kingdom and Ireland, strengthening its laboratory capabilities, including the provision of rabies and other infectious disease diagnostic testing, and enhancing its ability to deliver faster, more accurate diagnostic insights to veterinary professionals. Veterinary Pathology Group is a UK based provider of multi specialty veterinary diagnostic laboratory services, offering a broad suite of diagnostic testing solutions used to support clinical decision making in animal health, including tests relevant to rabies surveillance and diagnosis.

Regional Outlook

North America was the largest region in the rabies diagnostics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Rabies Diagnostics Market?

The rabies diagnostics market includes revenues earned by entities by providing diagnostic services such as reverse transcription followed by polymerase chain reaction (RT-PCR), virus isolation, and direct fluorescent antibody (DFA) tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.